<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7013637/table_4" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 4</label>
  <p>Cost effectiveness.</p>
 </caption>
 <thead>
  <tr>
   <th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" id="0-0-d">Discounted Costs (in €), SVR12 Rates and ICER (€/SVR12 Percentage Point)</th>
  </tr>
  <tr>
   <th align="center" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1" id="1-0-."> </th>
   <th align="center" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1" id="1-1-.">Costs (in €)</th>
   <th align="center" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1" id="1-2-.">SVR12 Percentage Point</th>
   <th align="center" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1" id="1-3-.">ICER (€/SVR12 Percentage Point)</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td align="left" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1">
    <b>Triple Therapies</b>
   </td>
   <td align="left" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1">171.017</td>
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.85 *</td>
   <td align="left" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1">–</td>
  </tr>
  <tr>
   <td align="left" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1">
    <b>DAA Therapies</b>
   </td>
   <td align="left" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1">206.184</td>
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.75 **</td>
   <td align="left" valign="bottom" style="border-bottom:solid thin" rowspan="1" colspan="1">€766.19/SVR12 Percentage Point</td>
  </tr>
 </tbody>
 <tfoot>
  <p class="fn" charset="fn">
   <p>* Mean of SVR12 rates boceprevir + pegylated interferon + ribavirin non-cirrhotic + cirrhotic [ 
    <a rid="B14-ijerph-17-00440" ref-type="bibr">14</a>]; ** Mean of SVR12 rates sofosbuvir + ledipasvir ± ribavirin non-cirrhotic + cirrhotic [ 
    <a rid="B14-ijerph-17-00440" ref-type="bibr">14</a>]; ICER—incremental cost-effectiveness ratio. 
   </p>
  </p>
 </tfoot>
</table>
